The association between psoriasis and carotid intima-media thickness (CIMT) or impaired flow-mediated dilation (FMD) remains controversial. We aimed to evaluate the extent of subclinical atherosclerosis as measured by CIMT and FMD in patients with psoriasis by conducting a meta-analysis.
INTRODUCTION
P soriasis is a chronic inflammatory skin disease characterized by relapsing thick scaling plaques. 1 The prevalence ranged from 0.91% to 8.5% in the adult population. 2 Among psoriatic patients, approximately 6% to 42% of the whites 3 and 1% to 9% Asian patients 4 were reported to have psoriatic arthritis. Psoriatic arthritis is defined as inflammatory arthritis associated with psoriasis. Psoriasis not only negatively affects the quality of life, but also increases risk of cardiovascular events 5 and cardiovascular mortality. 6 Therefore, early detection of subclinical atherosclerosis in psoriatic patients would help to reduce cardiovascular morbidity and mortality.
Endothelial function 7 and carotid intima-media thickness (CIMT) 8 have been suggested to be an important marker of subclinical atherosclerosis. Assessment of flow-mediated dilation (FMD) with high-resolution ultrasound in the brachial artery is a widely used method to evaluate the endothelial function. 9 CIMT is usually determined by using B-mode ultrasound technique in the common carotid artery. Determination of FMD and CIMT is widely used in clinical practice because of their noninvasive technique. Most studies have shown evidence of subclinical atherosclerosis in psoriatic patients as indicated by increased CIMT [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] or impaired FMD 14, 15, 17, 19, [24] [25] [26] than the matched controls. However, conflict findings regarding the relationship between psoriasis and subclinical atherosclerosis risk still exist. [27] [28] [29] [30] These conflicting results might be correlated with the severity or duration of psoriasis and population studied.
This meta-analysis aims to quantitatively estimate the association between psoriasis and subclinical atherosclerosis as measured by CIMT and FMD in patients with psoriasis by conducting a meta-analysis.
METHODS

Search Strategy
This study was conducted according to the recommendations of the Meta-Analysis of Observational Studies in Epidemiology. 31 This meta-analysis was not based on the individual participant data; ethical approval was not applicable. A systematic search of studies published before February 2015 was conducted through PubMed, Embase, Cochrane databases, China National Knowledge Infrastructure, and VIP databases. The following medical subject headings terms were used for the literature search: ''psoriasis'' OR ''psoriatic arthritis'' AND ''carotid intima-media thickness'' OR ''carotid atherosclerosis'' AND ''endothelial function'' OR ''flow-mediated dilation'' AND ''subclinical atherosclerosis''. Only fully published articles in peer-reviewed journals were included. The references of retrieved articles were also reviewed to identify any relevant study. brachial artery using ultrasound technique) or mean CIMT; reporting CIMT or FMD as continuous data for patients with psoriasis and controls; psoriatic patients and controls were at least age-and sex-matched. Exclusion criteria were: lack of an eligible control group; evaluating endothelial function except for FMD; studies did not provide CIMT or FMD as mean values and standard deviation (SD) or standard error.
Data Extraction and Quality Assessment
The following data were extracted from each included study: first author's name, publication year, geographic region, study design, type of psoriasis, psoriasis severity (Psoriasis Area and Severity Index score), characteristics of participants (number, age, gender), CIMT (mean and SD), FMD (mean and SD), matched factor, whether exclusion of cardiovascular risk factors in participant selection. The methodological quality of the selected studies was assessed by using the Newcastle-Ottawa Scale (NOS) 32 with the following 3 items: selection of the study groups, between-group comparability, and the ascertainment of either the exposure or the outcome. Study with NOS score !5 was judged to be of higher quality.
Statistical Analyses
CIMT and FMD were expressed as continuous data. The pooled effect size was calculated as the weighted mean difference (WMD) with 95% confidence interval (CI) by the inverse variance optimal approach between the psoriatic patients and control group. The degree of heterogeneity across studies was tested by using the I 2 statistic and Cochran Q statistic. A I 2 statistic value <50% or Cochran Q value of P < 0.05 was considered substantial heterogeneity. Random-effects analysis was used to estimate the effect size because of the anticipated clinical heterogeneity among included studies. The presence of publication bias was investigated by the Egger regression 33 and Begg correlation test with a P value <0.01, which is statistically significant. Subgroups analyses were performed according to the type of disease (psoriasis or psoriatic arthritis), study design (case-control or crosssectional), matched factor (matched BMI or not), mean age of psoriatic patients (>45 years or <45 years), and whether participants with cardiovascular risk factors were excluded. All statistical analyses were performed with Stata software 12.0 (Statacorp, College Station, TX).
RESULTS
Study Selection
The initial literature search yielded a total of 766 potentially relevant articles. After screening on the basis of abstracts or titles, 711 articles were excluded. After full manuscripts assessed for eligibility, 26 articles appeared to satisfy the inclusion criteria. Six articles were excluded for the following reasons: one study 35 FIGURE 2. Forest plots showing the weighted mean difference of carotid intima-media thickness between psoriatic patients and controls in a random-effects model. did not provide SD of the outcome; 2 studies 36,37 did not provide average intima-media thickness values; and participants' selection did not match with age or sex in 2 studies. 38, 39 One study 40 was further excluded because the reported FMD value was particularly high in both psoriatic patients and controls than other studies. Finally, only 20 studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 30 were included in the quantitative synthesis. The flowchart of the studies' selection process is outlined in Figure 1 .
Study Characteristics
Twenty studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 30 comprising 1066 psoriatic patients and 962 controls were included in the meta-analysis. The sample size of individual study ranged from 54 to 196. Of the 20 studies, 16 10, 11, [13] [14] [15] [16] [17] [18] [19] [21] [22] [23] 25, 27, 28, 30 were case-control studies, 3 12, 20, 24 were cross-sectional studies, and 1 26 was crosssectional plus case-control design. All the studies were published from 2007 to 2014. All studies clearly reported matching of patients and controls by sex and age design. Ten studies excluded participants with preexisting cardiovascular risk factors. The studies enrolled participants with a mean age range from 30 to 57.85 years. The characteristics of the included studies are shown in Table 1 . [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] 30 All quality scores of the included studies were >5 according to the NOS. NOS scores of the included studies are presented in Table 2 .
10-28,30
Psoriasis and CIMT
Sixteen studies [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 27, 30 assessed the CIMT difference in 934 psoriatic patients and 866 controls. As shown in Figure 2 , the pooled random-effect difference in CIMT indicated that psoriatic patients had a significant increase in CIMT compared with controls (WMD 0.11 mm; 95% CI 0.08-0.15). Substantial heterogeneity was observed (I 2 ¼ 90.7%; P < 0.001). Neither the Begg rank correlation test (P ¼ 0.137) nor the Egger linear regression test (P ¼ 0.634) showed evidence of publication bias.
Psoriasis and FMD
Eight studies 14, 15, 17, 19, [24] [25] [26] 28 assessed the FMD difference in 424 psoriatic patients and 400 controls. As shown in Figure 3 , the heterogeneity across the included trials was significant (I 2 ¼ 97%; P < 0.001), the pooled random-effect difference in FMD showed that psoriatic patients had a significant decrease in FMD than controls (WMD À2.79%; 95% CI À4.14% to À1.43%). Neither the Begg rank correlation test 
Subgroup and Sensitivity Analyses
Subgroup analyses showed that psoriatic arthritis alone appeared to have less CIMT (WMD 0.10 mm; 95% CI 0.06-0.15) and less impaired FMD (WMD À2.45%; 95% CI À2.73 to À2.18). Cardiovascular risk factors, age, and BMI of participants could influence the results. The detailed results of the subgroup analyses are shown in Table 3 
DISCUSSION
This meta-analysis suggests that patients with psoriasis are associated with an increased CIMT and impaired brachial artery FMD than the healthy controls, which reflects the subclinical atherosclerosis. Compared with controls, psoriatic patients had 2.79% reduction in brachial artery FMD and 0.11 mm thicker CIMT. Particularly, psoriatic arthritis had less impaired brachial artery FMD and thinner CIMT than total psoriatic patients.
When we investigated the relationship between psoriasis and subclinical atherosclerosis, the impact of type of disease, BMI, concomitant cardiovascular risk factors, and age should be considered. Subgroup analysis showed that patients with psoriatic arthritis appeared to have less impaired brachial artery FMD and thinner CIMT than the total psoriatic patients. CIMT may be affected by other cardiovascular risk factors. However, WMD of impaired FMD or increased CIMT remained statistically significant for participants without clinical evidence of atherosclerotic risk factors. These findings implied that the clustering of cardiovascular risk factors in psoriatic patients may amplify the effect of psoriasis on subclinical atherosclerosis. Psoriatic patients had a higher prevalence and incidence of obesity. 41 Subgroup analysis indicated that the pooled WMD of CIMT was increased when we pooled studies of matching factor with BMI. Together these findings, psoriatic patients were associated with accelerated subclinical atherosclerosis and might be independent of the classical atherosclerotic risk factors.
Elder people are usually associated with accelerated atherosclerosis. In this study, psoriatic patients with mean age >45 years appeared to have greater thicker CIMT than those younger than 45 years. On the contrary, the impaired brachial artery FMD was more pronounced in patients with mean age <45 years. Impaired endothelial function might precede any change in CIMT. These findings revealed that determination of FMD may be recommended for psoriatic patients with mean age <45 years, whereas measurement of CIMT might be suitable for the older patients.
The association between psoriasis and risk of cardiovascular disease is controversial. A well-designed meta-analysis suggested that psoriasis was associated with ischemic heart disease but not cerebrovascular disease and cardiovascular mortality. 42 Our meta-analyses indicated that patients with psoriasis were associated with excessive risk of subclinical atherosclerosis. Accordingly, a systematic review summarized that patients with psoriasis and psoriatic arthritis had impaired endothelial function compared with the general population, as measured by pulse wave velocity and aortic stiffness parameters. 43 A more recent published meta-analysis 44 suggested that patients with psoriatic arthritis appeared significantly associated with markers of subclinical atherosclerosis. However, this meta-analysis mainly focused on patients with psoriatic arthritis but not address total psoriatic patients. These meta-analyses supported that patients with psoriasis may increase future cardiovascular morbidity and mortality. The exact mechanisms of psoriasis in promoting atherosclerosis remain unclear. Psoriasis is considered a systemic inflammatory condition. The chronic systemic inflammatory state has been linked to an acceleration of the atherosclerotic lesions. Chronic systemic inflammation induces endothelial dysfunction, altered glucose metabolism, and insulin resistance that play a significant role in the progress of atherosclerosis. 45, 46 Moreover, many immunological factors involved in psoriasis, such as C-reactive protein and tumor necrosis factor-a, also contribute to atherosclerosis. 47 Several limitations should be considered. First, the causal association between subclinical atherosclerosis and psoriasis could not be defined because of the case-control or crosssectional nature of the included studies. Second, studies using other techniques to evaluate subclinical atherosclerosis were not included in this meta-analysis. Third, as for the included studies did not provide data about the severity or duration of psoriasis on the subclinical atherosclerosis, so we could not determine whether the severity of psoriasis or longer duration of the disease increased the extent of subclinical atherosclerosis. Fourth, significant heterogeneity in pooled CIMT (I 2 ¼ 90.7%) and FMD (I 2 ¼ 97%) was observed. The sources of heterogeneity might be correlated with the study design, age of the participant, presence or absence of psoriatic arthritis, and with or without atherosclerotic risk factors. Finally, we were unable to determine the effects of pharmacologic therapy on the progression of atherosclerosis in psoriatic patients.
CONCLUSIONS
This meta-analysis suggests that psoriatic patients are associated with excessive risk of subclinical atherosclerosis compared with the healthy controls. Assessment of CIMT and FMD of the brachial artery may be recommended to identify a subgroup of patients at higher risk for cardiovascular events in psoriatic patients. Psoriatic patients with mean age >45 years appeared to have greater thicker CIMTA and need frequent follow-up. Moreover, further studies are needed on whether the treatment of psoriasis will reverse subclinical atherosclerosis.
